Glucose Metabolism of Human Prostate Cancer Mouse Xenografts
We hypothesized that the glucose metabolism of prostate cancer is modulated by androgen. We performed in vivo biodistribution and imaging studies of [F-18] fluorodeoxyglucose (FDG) accumulation in androgen-sensitive (CWR-22) and androgen-independent (PC-3) human prostate cancer xenografts implanted...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2005-04-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1162/15353500200505118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544601688244224 |
|---|---|
| author | Hossein Jadvar Xiankui Li Antranik Shahinian Ryan Park Michel Tohme Jacek Pinski Peter S. Conti |
| author_facet | Hossein Jadvar Xiankui Li Antranik Shahinian Ryan Park Michel Tohme Jacek Pinski Peter S. Conti |
| author_sort | Hossein Jadvar |
| collection | DOAJ |
| description | We hypothesized that the glucose metabolism of prostate cancer is modulated by androgen. We performed in vivo biodistribution and imaging studies of [F-18] fluorodeoxyglucose (FDG) accumulation in androgen-sensitive (CWR-22) and androgen-independent (PC-3) human prostate cancer xenografts implanted in castrated and noncastrated male athymic mice. The growth pattern of the CWR-22 tumor was best approximated by an exponential function (tumor size in mm 3 = 14.913 e 0.108 × days , R 2 = .96, n = 5). The growth pattern of the PC-3 tumor was best approximated by a quadratic function (tumor size in mm 3 = 0.3511 × days 2 + 49.418 × day −753.33, R 2 = .96, n = 3). The FDG accumulation in the CWR-22 tumor implanted in the castrated mice was significantly lower, by an average of 55%, in comparison to that implanted in the noncastrated host (1.27 vs. 2.83, respectively, p < .05). The 3-week maximal standardized uptake value (SUV max ) was 0.99 ± 0.43 (mean ± SD ) for CWR-22 and 1.21 ± 0.32 for PC-3, respectively. The 5-week SUV max was 1.22 ± 0.08 for CWR-22 and 1.35 ± 0.17 for PC-3, respectively. The background muscle SUV max was 0.53 ± 0.11. Glucose metabolism was higher in the PC-3 tumor than in the CWR-22 tumor at both the 3-week (by 18%) and the 5-week (by 9.6%) micro-PET imaging sessions. Our results support the notions that FDG PET may be useful in the imaging evaluation of response to androgen ablation therapy and in the early prediction of hormone refractoriness in men with metastatic prostate cancer. |
| format | Article |
| id | doaj-art-258b37194b724e05a3d321c0987f988f |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2005-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-258b37194b724e05a3d321c0987f988f2025-02-03T10:08:00ZengSAGE PublishingMolecular Imaging1536-01212005-04-01410.1162/1535350020050511810.1162_15353500200505118Glucose Metabolism of Human Prostate Cancer Mouse XenograftsHossein JadvarXiankui LiAntranik ShahinianRyan ParkMichel TohmeJacek PinskiPeter S. ContiWe hypothesized that the glucose metabolism of prostate cancer is modulated by androgen. We performed in vivo biodistribution and imaging studies of [F-18] fluorodeoxyglucose (FDG) accumulation in androgen-sensitive (CWR-22) and androgen-independent (PC-3) human prostate cancer xenografts implanted in castrated and noncastrated male athymic mice. The growth pattern of the CWR-22 tumor was best approximated by an exponential function (tumor size in mm 3 = 14.913 e 0.108 × days , R 2 = .96, n = 5). The growth pattern of the PC-3 tumor was best approximated by a quadratic function (tumor size in mm 3 = 0.3511 × days 2 + 49.418 × day −753.33, R 2 = .96, n = 3). The FDG accumulation in the CWR-22 tumor implanted in the castrated mice was significantly lower, by an average of 55%, in comparison to that implanted in the noncastrated host (1.27 vs. 2.83, respectively, p < .05). The 3-week maximal standardized uptake value (SUV max ) was 0.99 ± 0.43 (mean ± SD ) for CWR-22 and 1.21 ± 0.32 for PC-3, respectively. The 5-week SUV max was 1.22 ± 0.08 for CWR-22 and 1.35 ± 0.17 for PC-3, respectively. The background muscle SUV max was 0.53 ± 0.11. Glucose metabolism was higher in the PC-3 tumor than in the CWR-22 tumor at both the 3-week (by 18%) and the 5-week (by 9.6%) micro-PET imaging sessions. Our results support the notions that FDG PET may be useful in the imaging evaluation of response to androgen ablation therapy and in the early prediction of hormone refractoriness in men with metastatic prostate cancer.https://doi.org/10.1162/15353500200505118 |
| spellingShingle | Hossein Jadvar Xiankui Li Antranik Shahinian Ryan Park Michel Tohme Jacek Pinski Peter S. Conti Glucose Metabolism of Human Prostate Cancer Mouse Xenografts Molecular Imaging |
| title | Glucose Metabolism of Human Prostate Cancer Mouse Xenografts |
| title_full | Glucose Metabolism of Human Prostate Cancer Mouse Xenografts |
| title_fullStr | Glucose Metabolism of Human Prostate Cancer Mouse Xenografts |
| title_full_unstemmed | Glucose Metabolism of Human Prostate Cancer Mouse Xenografts |
| title_short | Glucose Metabolism of Human Prostate Cancer Mouse Xenografts |
| title_sort | glucose metabolism of human prostate cancer mouse xenografts |
| url | https://doi.org/10.1162/15353500200505118 |
| work_keys_str_mv | AT hosseinjadvar glucosemetabolismofhumanprostatecancermousexenografts AT xiankuili glucosemetabolismofhumanprostatecancermousexenografts AT antranikshahinian glucosemetabolismofhumanprostatecancermousexenografts AT ryanpark glucosemetabolismofhumanprostatecancermousexenografts AT micheltohme glucosemetabolismofhumanprostatecancermousexenografts AT jacekpinski glucosemetabolismofhumanprostatecancermousexenografts AT petersconti glucosemetabolismofhumanprostatecancermousexenografts |